Evaxion Biotech A/S (EVAX)
1.81
-0.13 (-6.70%)
At close: Mar 03, 2025, 3:59 PM
1.89
4.25%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.83 |
| Market Cap | 568.03K |
| Revenue (ttm) | 37.48K |
| Net Income (ttm) | -130.43K |
| EPS (ttm) | -14 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -1.56 |
| Analyst | Buy |
| Ask | 1.95 |
| Volume | 106,844 |
| Avg. Volume (20D) | 2,512,274 |
| Open | 1.94 |
| Previous Close | 1.94 |
| Day's Range | 1.78 - 1.95 |
| 52-Week Range | 1.78 - 22.05 |
| Beta | -0.27 |
About EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol EVAX
Website https://www.evaxion-biotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for EVAX stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 672.24% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Evaxion Biotech A/S is scheduled to release its earnings on Mar 26, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-8.56%
Evaxion Biotech shares are trading lower. The stoc...
Unlock content with
Pro Subscription
1 month ago
-27.14%
Evaxion Biotech shares are trading lower after the company announced a public offering of 3,997,361 ADS.
